Omeprazol Teva (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Teva, is a proton pump inhibitor presented as an oral dosage form for systemic use. It reduces gastric acid production and is employed in the management of acid‑related disorders such as gastro‑oesophageal reflux disease, peptic ulcer disease and ulcer prevention in patients taking NSAIDs.

GNH USA supplies Omeprazol Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and provides regulatory documentation for global distribution.

Omeprazole is indicated for several acid‑related gastrointestinal conditions, acting to reduce gastric acidity.

- Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and esophageal irritation by lowering acid exposure. - Peptic ulcer disease: promotes ulcer healing and prevents recurrence by maintaining a higher gastric pH. - NSAID‑induced gastric ulcer: reduces the risk of ulcer formation in patients receiving non‑steroidal anti‑inflammatory drugs. - Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens by creating a less acidic environment for bacterial clearance.

Omeprazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Abdominal pain: discomfort or cramping in the stomach region. - Nausea: feeling of queasiness that may resolve with continued use. - Diarrhea: loose stools that are usually transient. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis, angioedema): swelling, rash, difficulty breathing. - Clostridioides difficile infection: severe diarrhea and colitis. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Vitamin B12 deficiency: anemia, neuropathy with long‑term use. - Bone fractures: increased risk with prolonged therapy. - Acute interstitial nephritis: kidney inflammation presenting with fever and rash.

When prescribing Omeprazol Teva, clinicians should consider several safety and handling points.

- Assess renal function: adjust use in patients with severe impairment. - Monitor for infection: prolonged therapy may increase risk of gastrointestinal infections. - Evaluate need for long‑term therapy: consider step‑down strategies after symptom control. - Review concomitant medications: check for potential drug interactions. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Omeprazole can affect the pharmacokinetics of several medicines, requiring attention to potential interactions.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atazanavir: decreased absorption, leading to sub‑therapeutic levels. - High‑dose methotrexate: increased toxicity due to reduced renal clearance.

Moderate Interactions (Monitor Closely): - Warfarin: possible elevation of INR, requiring more frequent monitoring. - Diazepam: increased plasma concentrations, may enhance sedation. - Digoxin: altered absorption, may necessitate dose adjustment.